FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:660-662 March 7, 1996 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The main function of red cells is to transport oxygen from the lungs to the peripheral tissues. Erythropoietin controls red-cell production by stimulating the differentiation of erythroid progenitor cells in the bone marrow. The hormone originates mainly in specialized interstitial renal cells, which respond to a decrease in oxygen delivery by increasing their production of erythropoietin. The purification of erythropoietin from the urine of patients with aplastic anemia by Miyake et al.¹ permitted cloning of the erythropoietin gene in 1985. The commercial production of recombinant erythropoietin soon followed, opening the way to the first clinical trials of a hematopoietic growth . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Praditpornsilpa, K., Buranasot, S., Bhokaisuwan, N., Avihingsanon, Y., Pisitkul, T., Kansanabuch, T., Eiam-Ong, S., Chusil, S., Intarakumtornchai, T., Tungsanga, K. (2005). Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation. Nephrol Dial Transplant 20: 626-630 [Full Text]